header__brand

Prescription Drug Abuse

The abuse of prescription drugs continues to be a major concern for both state and federal governments. Efforts to address this epidemic have ranged from instituting prescribing limitations to mandating prescriber education. OMSs are part of the solution to this problem. This is evidenced by the numerous educational resources AAOMS offers to our members as well as membership survey data showing a reduction in the amount of opioids OMSs prescribe for wisdom teeth removal. However, we do not support unnecessarily inhibiting our ability to effectively treat real patient pain.

Federal Comment Letters
Date

Comment Letter to Pain Mgmt. Best Practices Inter-Agency Task Force

June 14, 2018

AAOMS Comment Letter to House Leadership Re: Opioid Abuse

June 11, 2018

AAOMS Letter to House Sponsors of the CARA 2.0 Act of 2018 Re: Prescription Drug Abuse

April 09, 2018

AAOMS Letter to House Energy and Commerce Health Subcommittee Re: Prescription Drug Abuse

April 09, 2018

AAOMS Letter to Senate Sponsors of the CARA 2.0 Act of 2018 Re: Prescription Drug Abuse

April 09, 2018

AAOMS Letter to Senate HELP Committee Re: Prescription Drug Abuse

April 09, 2018

AAOMS Letter of Comment to FDA Re: Opioid Steering Committee

December 19, 2017

AAOMS Support Letter to Senate HELP Leadership Regarding Hearing on Fed. Response to the Opioid Crisis

October 02, 2017

AAOMS Support Letter to House E&C Committee Leadership Regarding Meeting to Discuss the Opioid Epidemic

September 29, 2017

Support Letter to Senate HELP Committee Regarding Opioid Epidemic

October 02, 2017

AAOMS Comment Letter to Sen. Richard Durbin Re: Prescription Drug Abuse

May 18, 2016

AAOMS submits support letter to Rep. Clark (D-MA) and E&C Health Subcommitte on HR 4955, the Reducing Unused Medications Act of 2016

April 20, 2016

AAOMS sends support letter to Senator Elizabeth Warren (D-MA) for S. 2578, the Reducing Unused Medications Act of 2016

April 18, 2016

AAOMS Comment Letter to the FDA Re: Innovative Disposal Systems, Technologies or Designs to Prevent or Deter Misuse and Abuse of Opioid Analgesics

June 01, 2014

Coalition Comment Letter to DEA Re: The Reclassification of Hydrocodone-containing Combination Drug

March 01, 2014

Coalition Comment Letter to HHS Re: The Reclassification of Hydrocodone-containing Combination Drug

February 01, 2014

Coalition Letter to US Senate Re: Opposition to Amendment Included in the FDA Safety and Innovation Act (S. 3187) that Would Reclassify Hydrocodone-containing Combination Products as Schedule II

June 11, 2012